United Therapeutics grants equity awards to director

United Therapeutics granted director Linda Maxwell annual non-employee director equity awards on 2026-07-22, consisting of 380 restricted stock units and 1,190 stock options on common stock.

Rhea-AI Filing Summary

United Therapeutics granted director Linda Maxwell annual non-employee director equity awards on 2026-07-22, consisting of 380 restricted stock units and 1,190 stock options on common stock. The options carry a $527.0700 exercise price and expire on 2033-07-22.

Each restricted stock unit represents one share of common stock after vesting and has no expiration date. Both awards become fully vested on the earlier of one year from grant or the anticipated June 25, 2027 Annual Meeting of Shareholders. No sales or dispositions were reported.

Insider Trade Summary

Grant/Award: 1,570 shares

Grant/Award 2 txns

Insider MAXWELL LINDA

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Unit F1, F2, F3, F4	380	$0.00	$0.00
Grant/Award	Stock Option F2, F3	1,190	$0.00	$0.00

Holdings After Transaction: Restricted Stock Unit — 380 contracts (Direct); Stock Option — 1,190 contracts (Direct)

Footnotes (4)

1. F1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.
2. F2. Annual non-employee director award.
3. F3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.
4. F4. Not applicable as restricted stock units do not have an expiration date.

Key Figures

Restricted stock units granted: 380 units Stock options granted: 1190 options Option exercise price: $527.0700 per share +4 more

7 metrics

Restricted stock units granted 380 units Annual non-employee director award to Linda Maxwell on 2026-07-22

Stock options granted 1190 options Annual non-employee director award to Linda Maxwell on 2026-07-22

Option exercise price $527.0700 per share Exercise price for 1,190 stock options on United Therapeutics common stock

RSU underlying shares 380 shares Each restricted stock unit represents one share of common stock after vesting

Option underlying shares 1190 shares Common shares underlying the stock options granted to Linda Maxwell

Vesting reference date June 25, 2027 Anticipated date of the next Annual Meeting of Shareholders used in vesting condition

Option expiration date 2033-07-22 Scheduled expiration date of the stock options if not exercised

Key Terms

Restricted Stock Unit, Stock Option, exercise price, Annual non-employee director award, +1 more

5 terms

Restricted Stock Unit financial

"Each restricted stock unit represents the right to receive, following vesting"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Stock Option financial

"Stock Option award covering 1190.0000 underlying shares of common stock"

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

exercise price financial

"conversion_or_exercise_price of 527.0700 applies to the stock option grant"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Annual non-employee director award financial

"Annual non-employee director award describes the RSU and option grants"

Annual Meeting of Shareholders regulatory

"Vesting occurs by the date of the next Annual Meeting of Shareholders"

A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity awards did United Therapeutics (UTHR) grant to director Linda Maxwell?

United Therapeutics granted Linda Maxwell 380 restricted stock units and 1,190 stock options as annual non-employee director awards. The options are exercisable for common stock at $527.0700 per share, alongside RSUs that each convert into one share upon vesting.

When do Linda Maxwell’s new United Therapeutics (UTHR) equity awards vest?

The awards vest fully on the earlier of one year from the July 22, 2026 grant or the next Annual Meeting. The anticipated next Annual Meeting of Shareholders is on June 25, 2027, which would accelerate vesting if it occurs before the one-year anniversary.

What are the key terms of Linda Maxwell’s United Therapeutics (UTHR) stock options?

Maxwell received options on 1,190 shares of United Therapeutics common stock with a $527.0700 exercise price. These options vest on the same schedule as her RSUs and are scheduled to expire on July 22, 2033 if not exercised earlier.

How do Linda Maxwell’s United Therapeutics (UTHR) restricted stock units work?

Each of Maxwell’s 380 restricted stock units represents the right to receive one share of United Therapeutics common stock after vesting. The RSUs have no expiration date; they are tied to the vesting schedule linked to the one-year anniversary or Annual Meeting.

Were Linda Maxwell’s United Therapeutics (UTHR) equity awards under a Rule 10b5-1 trading plan?

The filing’s Rule 10b5-1 checkbox is not marked, indicating these equity awards were not made under a pre-arranged 10b5-1 trading plan. They are characterized as annual non-employee director compensation grants rather than trades executed under such a plan.

Did director Linda Maxwell sell any United Therapeutics (UTHR) shares in this Form 4?

No sales or dispositions were reported; all transactions were acquisitions of derivative securities as part of equity awards. The Form 4 lists only grants of restricted stock units and stock options, with no corresponding share sales or exercises on that date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 07/23/2026 - 04:46 PM Accepted by SEC EDGAR 07/23/2026 - 04:46 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MAXWELL LINDA

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MARYLAND 20910

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/22/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0.00(1)	07/22/2026		A		380(2)		06/25/2027(3)	(4)	Common Stock	380	$0.00	380	D
Stock Option	$527.07	07/22/2026		A		1,190(2)		06/25/2027(3)	07/22/2033	Common Stock	1,190	$0.00	1,190	D

Explanation of Responses:

1. Each restricted stock unit represents the right to receive, following vesting, one share of United Therapeutics Corporation common stock.

2. Annual non-employee director award.

3. Annual non-employee director awards become fully vested on the earlier to occur of (a) the one-year anniversary of the grant date; or (b) the date of the next Annual Meeting of Shareholders following the grant date. June 25, 2027 is the anticipated date of the next Annual Meeting of Shareholders.

4. Not applicable as restricted stock units do not have an expiration date.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	07/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)